Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs

At the beginning of 2011, the early benefit assessment of new drugs was introduced in Germany with the Act on the Reform of the Market for Medicinal Products (AMNOG). The Federal Joint Committee (G‐BA) generally commissions the Institute for Quality and Efficiency in Health Care (IQWiG) with this ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Skipka, Guido, Wieseler, Beate, Kaiser, Thomas, Thomas, Stefanie, Bender, Ralf, Windeler, Jürgen, Lange, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034755/
https://www.ncbi.nlm.nih.gov/pubmed/26134089
http://dx.doi.org/10.1002/bimj.201300274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034755/
https://www.ncbi.nlm.nih.gov/pubmed/26134089
http://dx.doi.org/10.1002/bimj.201300274

Ejemplares similares